TY - JOUR T1 - Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon JF - Journal of Neurology, Neurosurgery & Psychiatry JO - J Neurol Neurosurg Psychiatry SP - 693 LP - 700 DO - 10.1136/jnnp-2022-328792 VL - 93 IS - 7 AU - Gargi Banerjee AU - Kiran Samra AU - Matthew E Adams AU - Zane Jaunmuktane AU - Adrian Robert Parry-Jones AU - Joan Grieve AU - Ahmed K Toma AU - Simon F Farmer AU - Richard Sylvester AU - Henry Houlden AU - Peter Rudge AU - Simon Mead AU - Sebastian Brandner AU - Jonathan M Schott AU - John Collinge AU - David J Werring Y1 - 2022/07/01 UR - http://jnnp.bmj.com/content/93/7/693.abstract N2 - In the last 6 years, following the first pathological description of presumed amyloid-beta (Aβ) transmission in humans (in 2015) and subsequent experimental confirmation (in 2018), clinical cases of iatrogenic cerebral amyloid angiopathy (CAA)—attributed to the transmission of Aβ seeds—have been increasingly recognised and reported. This newly described form of CAA is associated with early disease onset (typically in the third to fifth decade), and often presents with intracerebral haemorrhage, but also seizures and cognitive impairment. Although assumed to be rare, it is important that clinicians remain vigilant for potential cases, particularly as the optimal management, prognosis, true incidence and public health implications remain unknown. This review summarises our current understanding of the clinical spectrum of iatrogenic CAA and provides a diagnostic framework for clinicians. We provide clinical details for three patients with pathological evidence of iatrogenic CAA and present a summary of the published cases to date (n=20), identified following a systematic review. Our aims are: (1) To describe the clinical features of iatrogenic CAA, highlighting important similarities and differences between iatrogenic and sporadic CAA; and (2) To discuss potential approaches for investigation and diagnosis, including suggested diagnostic criteria for iatrogenic CAA. ER -